NAVINCI DIAGNOSTICS AB

Their core work

Navinci Diagnostics AB is a Swedish biotech SME based in Uppsala specializing in diagnostic technologies applied to biomedical research. Their H2020 footprint spans two distinct application areas: dynamic hormone measurement (ULTRADIAN project) and vascular rare disease research (V.A. Cure), suggesting they provide detection or assay technologies that can be deployed across multiple disease contexts. As an SME with a website historically linked to Olink Bioscience — a Uppsala-based pioneer in proximity ligation assay (PLA) protein detection — they likely contribute proprietary measurement platforms to academic and clinical research consortia. Their value to partners is as a technology provider that bridges laboratory diagnostics and translational biomedical research.

What they specialise in

How they've shifted over time

In the first half of their H2020 participation (ULTRADIAN, 2015–2020), Navinci was engaged in dynamic hormone measurement — a relatively focused diagnostic application with no preserved keyword data, suggesting a contained, technology-provider role. By the later period (V.A. Cure, 2019–2023), their project footprint shifted markedly toward rare vascular disease, incorporating genetics, next-generation sequencing, cellular and animal models, and drug repurposing. This trajectory suggests their underlying diagnostic platform became applicable to more complex, multi-modal disease research contexts over time.

Navinci appears to be moving from narrow endocrine diagnostics toward broader rare disease and precision medicine contexts, making them an increasingly relevant partner for consortia working on genetic vascular conditions or somatic mutation-driven pathologies.

How they like to work

Navinci has never led an H2020 project — they appear exclusively as participant or third party, which is typical of a specialist SME that contributes a specific technology or platform rather than driving scientific agendas. With 22 unique partners across 8 countries from only 2 projects, they were embedded in relatively large, diverse consortia rather than small bilateral collaborations. This profile suggests working with them means accessing a focused technical capability, not co-designing the research direction.

Despite only two projects, Navinci reached 22 unique consortium partners across 8 countries — a relatively broad European network for an SME of this size. This suggests the consortia they joined were large, multi-partner efforts rather than focused bilateral collaborations.

What sets them apart

Navinci Diagnostics sits at the intersection of commercial diagnostic assay development and academic biomedical research — a rare SME position that lets them bring validated, deployable measurement tools into grant-funded projects. Based in Uppsala, Sweden's leading life science cluster, and linked to the Olink Bioscience ecosystem, they carry proximity to world-class proteomics and molecular detection expertise. For a consortium needing a diagnostic technology partner that can operate across hormone biology and rare vascular disease, Navinci offers an unusual breadth of application domain experience for their size.

Highlights from their portfolio

• V.A. Cure
  A multidisciplinary rare disease consortium (2019–2023) addressing vascular anomalies through genetics, NGS, and drug repurposing — Navinci's most scientifically complex project and the source of nearly all their documented technical keywords.
• ULTRADIAN
  A five-year Health pillar RIA (2015–2020) on dynamic hormone diagnostics where Navinci served as a direct participant, reflecting their foundational role in measurement technology for endocrine research.